AB Science announces a slight delay in the publication of its 2025 half-year financial report

Core Viewpoint - AB Science has announced a slight delay in the publication of its half-year financial report for 2025, which is now scheduled for October 10, 2025, to allow auditors to complete their work [1][2]. Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs), targeting diseases with high unmet medical needs [3]. - The company has developed a proprietary portfolio of molecules, with its lead compound, masitinib, registered for veterinary medicine and under development for human medicine in various fields including oncology and neurological diseases [4].